Many factors including PD-L1 expression, tumor neoantigen expression and delivery, related cellular signaling pathways, tumor microenvironment, epigenetic modifications have been confirmed to involved in the response to PD-1/PD-L1 blockade therapy (68). This evidence concerns the gene CD274 and neoplasm.